Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
See how to make money instead of spending it on Black Friday with this offer (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
NASDAQ:PCRX

Pacira BioSciences - PCRX Stock Forecast, Price & News

$49.60
+0.64 (+1.31%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$48.88
$50.11
50-Day Range
$47.50
$57.45
52-Week Range
$46.03
$82.16
Volume
58,451 shs
Average Volume
427,782 shs
Market Capitalization
$2.28 billion
P/E Ratio
120.98
Dividend Yield
N/A
Price Target
$77.33

Pacira BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
55.9% Upside
$77.33 Price Target
Short Interest
Bearish
11.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.36
Upright™ Environmental Score
News Sentiment
0.94mentions of Pacira BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$80,040 Sold Last Quarter
Proj. Earnings Growth
82.69%
From $2.08 to $3.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

98th out of 1,044 stocks

Pharmaceutical Preparations Industry

41st out of 510 stocks

PCRX stock logo

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

Pacira BioSciences (NASDAQ:PCRX) Hits New 12-Month Low at $46.90
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira (PCRX) Lags Q3 Earnings Estimates
Pacira BioSciences: Q3 Earnings Insights
Assessing Pacira BioSciences' Growth Prospects
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings
11/03/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
697
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.33
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+55.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$41.98 million
Pretax Margin
3.85%

Debt

Sales & Book Value

Annual Sales
$541.53 million
Cash Flow
$3.54 per share
Book Value
$16.78 per share

Miscellaneous

Free Float
43,083,000
Market Cap
$2.28 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. David M. StackMr. David M. Stack (Age 72)
    Chairman & CEO
    Comp: $5.35M
  • Mr. Charles A. Reinhart IIIMr. Charles A. Reinhart III (Age 61)
    CPA, M.B.A., Chief Financial Officer
    Comp: $880.8k
  • Dr. Roy Winston M.D. (Age 60)
    Chief Medical Officer
    Comp: $996.94k
  • Mr. Max ReinhardtMr. Max Reinhardt (Age 51)
    Pres of Rest of World
    Comp: $1.05M
  • Dr. Jonathan Slonin M.D. (Age 47)
    Chief Clinical Officer
    Comp: $815.25k
  • Mr. Daryl Gaugler (Age 60)
    Chief Operating Officer
  • Ms. Lauren Bullaro Riker (Age 43)
    Principal Accounting Officer & VP of Fin.
  • Mr. Charles Laranjeira (Age 56)
    Chief Technical Officer
  • Ms. Kristen Williams J.D. (Age 48)
    Chief Admin. Officer & Sec.
  • Susan Mesco
    Head of Investor Relations













PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price forecast for 2023?

8 brokers have issued 1-year price objectives for Pacira BioSciences' shares. Their PCRX share price forecasts range from $60.00 to $96.00. On average, they expect the company's stock price to reach $77.33 in the next year. This suggests a possible upside of 55.9% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2022?

Pacira BioSciences' stock was trading at $60.17 on January 1st, 2022. Since then, PCRX shares have decreased by 17.6% and is now trading at $49.60.
View the best growth stocks for 2022 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Thursday, November, 3rd. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.02. The company earned $167.47 million during the quarter, compared to analysts' expectations of $167.30 million. Pacira BioSciences had a net margin of 3.19% and a trailing twelve-month return on equity of 12.34%.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its third quarter 2022 earnings guidance on Thursday, October, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $167.50 million-$167.50 million, compared to the consensus revenue estimate of $172.72 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.61%), Macquarie Group Ltd. (6.39%), Baillie Gifford & Co. (4.07%), Renaissance Technologies LLC (3.82%), Armistice Capital LLC (3.47%) and Spyglass Capital Management LLC (2.73%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Dennis Mcloughlin, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $49.60.

How much money does Pacira BioSciences make?

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $2.28 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Pacira BioSciences have?

The company employs 697 workers across the globe.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 11/27/2022 by MarketBeat.com Staff